BOYNTON BEACH, FL
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)STEM CELL CANCER AND REGENERATIVE MEDICINE RESEARCH INC, founded in 2007, is a micro nonprofit in the Medical Research sector that reported $15K in total revenue in fiscal year 2023. Revenue decreased 19% compared to the prior year. Expenses of $37K exceeded revenue, resulting in a 152% operating deficit.
THE ORGANIZATION IS TO BE OPERATED FOR SCIENTIFIC AND EDUCATIONAL PURPOSES TO CONDUCT RESEARCH TO UNCOVER THE MOLECULAR BASIS OF CANCER AND DEGENERATIVE DISEASE WITH THE EMPHASIS ON CANCER INCLUDING MULTIPLE MYELOMA AND OTHER CHRONIC DISEASES INCLUDING FRAILTY.
IN MAY 2008 THE ORGANIZATION STARTED A COLLABORATION WITH SCIENTISTS AT WAKE FOREST UNIVERSITY WHO HAVE DEVELOPED A PROTOCOL FOR USING GRANULOCYTES FOR TREATING SOLID TUMRORS. THE PROTOCOL WAS...
IN MAY 2008 THE ORGANIZATION STARTED A COLLABORATION WITH SCIENTISTS AT WAKE FOREST UNIVERSITY WHO HAVE DEVELOPED A PROTOCOL FOR USING GRANULOCYTES FOR TREATING SOLID TUMRORS. THE PROTOCOL WAS MODIFIED FOR IMPLEMENTATION AND INVESTIGATIONAL NEW DRUG APPROVAL WAS OBTAINED IN OCTOBER 2008 FOR A PHASE I/II CLINICAL TRIAL FOR 29 PATIENTS. WESTERN INSTITUTIONAL REVIEW BOARD APPROVAL WAS OBTAINED IN NOVEMBER 2008. THROUGH 2023, 17 PATIENTS HAVE BEEN TREATED AND 260 DONORS HAVE BEEN EVALUATED.
YOUNG BLOOD CLINICAL STUDY UNDER FOOD AND DRUG ADMINISTRATION APPROVAL EVALUATING THE SAFETY AND EFFICACY OF FRESH FROZEN PLASMA (GMFFP) FROM YOUNG HEALTHY DONORS AGES 18 TO 35, WHO HAVE GRANULOCYTE...
YOUNG BLOOD CLINICAL STUDY UNDER FOOD AND DRUG ADMINISTRATION APPROVAL EVALUATING THE SAFETY AND EFFICACY OF FRESH FROZEN PLASMA (GMFFP) FROM YOUNG HEALTHY DONORS AGES 18 TO 35, WHO HAVE GRANULOCYTE - COLONY STIMULATING FACTOR (G-CSF) TO AMELIORATE FRAILTY AND ENHANCE THE IMMUNE RISK PROFILE IN OLDER INDIVIDUALS.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2023 | 2022 | Change | |
|---|---|---|---|
| Revenue | $14,514 | $18,013 | -0.2% |
| Expenses | $36,558 | $94,674 | -0.6% |
| Net Income | $-22,044 | $-76,661 | -0.7% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| SUSAN MAHARAJ | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| DANIEL MANGRU | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| DIPNARINE MAHARAJ MD | PRESIDENT, D | 6.00 |
Officer
Director
|
$0 | $0 | $0 |
| JACQUELINE GOUVEA MD | SECRETARY, T | 4.00 |
Officer
Director
|
$0 | $0 | $0 |
| CLAUDIA OLIVEIRA | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| RICHARD SIMON | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| TYLER SMILEY | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| TERRELL W WITCHER | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2024 | No data | No data | No data | No data |
| 2023 | $14,514 | $36,558 | $559,018 | $-22,044 |
| 2022 | $18,013 | $94,674 | $580,762 | $-76,661 |
| 2021 | $240,841 | $275,836 | $656,469 | $-34,995 |
| 2020 | $227,703 | $340,717 | $690,314 | $-113,014 |
| 2019 | $754,887 | $328,726 | $802,237 | $426,161 |
| 2018 | $129,690 | $70,834 | $375,301 | $58,856 |
Compare STEM CELL CANCER AND REGENERATIVE MEDICINE RESEARCH INC with other nonprofits in Florida and across the country.